Neuroprotective potential of 17-oximino-16-arylidene steroids: In vivo and in silico investigations.

Several recent literature reports indicate the strong neuroprotective potential of synthetic heterosteroids, still search for potent, safer and effective neuroprotective steroidal molecules continues. In the current study, a new series of 17-oximino-16-substituted steroids (1-8) has been evaluated in MPTP-induced Parkinson's disease in mice and amyloid-β induced Alzheimer's disease in rats with an intention to discover an effective and efficient neuroprotective molecule. Behavioural studies followed by histopathological and estimation of the several neuroinflammatory biochemical parameters such as acetylcholinesterase, lipid peroxide, reactive oxygen, and nitric oxide species were carried out.

Secretome Analysis of Prostate Cancer Cell Lines Reveals Cell Cycle-Dependent PSA Secretion and Potential Biomarkers.

Metastatic prostate cancer (mPCa) is marked by heterogeneity and therapy resistance, which arise from prolonged therapy regimens. This heterogeneity is reflected in various morphologic and genetic characteristics, biomarker expression, and other molecular mechanisms, thereby contributing to the complexity of the disease. To investigate tumor heterogeneity, the effects of androgen targeting therapy (ADT) on single-cell PSA secretion was assessed by analyzing the prostate cancer cell lines using a modified ELISpot platform.

Comparison of Standard and Global Coagulation Tests in Hemodialysis Patients.

Background: Chronic kidney disease (CKD) is associated with an increased tendency of bleeding and thrombosis. There are multiple factors that interact with each other to cause either in CKD patients. Conventional or standard coagulation tests (SCT) have several limitations.

A Randomized trial of stereotactic body radiation therapy vs radiofrequency ablation for the treatment of small renal masses: A feasibility study (RADSTER).

Objective: To evaluate the feasibility of a trial comparing stereotactic beam radiotherapy (SBRT) and radiofrequency ablation (RFA) for small renal masses (SRM).

Methods: Patients opting for treatment of a SRM at a single center were randomized 1:1 to SBRT or RFA. Crossover if ineligible for treatment after randomization was allowed.